Missed it by that much

Adam H.H. Altman, MD Capt, USAF, MC, FS Ophthalmology, R1 09 Jan 2019



Disclosures

No financial disclosures

DoD Disclaimer

 "The views expressed are those of the presenter and do not reflect the official views or policy of the Department of Defense or its Components"

HPI

• 30yo F initially underwent LASIK in 2014. Reports blurred vision OS since POD #1.

Past History

POHx: LASIK July 2014 OU (details next slide)

Ocular meds: None

PMHx: None

PSHx: None

Soc Hx: None

Allergies: NKDA

Fam OHx: None

Pre-op LASIK: July 2014

	OD	os
UCVA	20/400	20/400
BCVA	20/15	20/15
Manifest Rx	-7.25 – 0.50 x 030	-7.75 – 0.25 x 170
K1/2	44.00 / 45.00	44.12 / 44.87

Treatment: 21 July 2014

	OD	os
Treatment	-7.39 – 0.67 x 027	-7.88 – 0.30 x 001
Optical / Ablation Zones	6.2 x 6.0mm / 8.0mm	6.1 x 6.0mm / 8.0mm
Total ablation depth	123um	120um
ActiveTrak	Enabled, Auto Centering	Not Enabled, Manually tracked
Iris Registration	Enabled, 6.1 Counterclockwise	Not Enabled

Post-op VA 2014

Post-op	OD UCVA	OS UCVA	OS BCVA
Day 1	20/25	20/150	
1 week	20/20	20/100-	20/80
2 weeks	20/20	20/70-	
1 month	20/15	20/70-	20/70-
3 month	20/15	20/80+	20/30
6 month	20/15	20/70-	20/60
11 month	20/15	20/80-	20/70
12 month	20/15	20/60 (scleral lens)	20/40-
4 year	20/15	20/70-	20/40


SLE: 26 June 2018

	OD	os
Ext	No ptosis/proptosis	No ptosis/proptosis
LLL	Normal	Normal
C/S	W&Q	W&Q
K	Clear, No haze/scarring	Clear, No haze/scarring
A/C	D&Q	D&Q
I	R&F	R&F
L	Clear	Clear
Vit	Clear	Clear


Dilated Fundus Exam

- OD: Disc: C/D 0.30; Vitreous clear; Macula: flat; Vessels: wnl; Periphery: flat 360
- OS: Disc: C/D 0.30; Vitreous clear; Macula: flat; Vessels: wnl; Periphery: flat 360


26 June 2018: Topo OD




26 June 2018: Topo OS



Immediate Post-op July 2014: Topo



Feb 2018: Topo



DDx \ VA s/p LASIK at 4 years out

- Over / under treatment
- Ectasia
- Regression
- Decentered ablation

Over / under treatment?

	OD	os
Manifest Rx	-7.25 – 0.50 x 030	-7.75 – 0.25 x 170
Treatment	-7.39 – 0.67 x 027	-7.88 – 0.30 x 001


DDx \ VA s/p LASIK at 4 years out


- Over / under treatment
- Ectasia
- Regression
- Decentered ablation

Regression / Ectasia?

31 July 2014

08 Feb 2018






DDx \ VA s/p LASIK at 4 years out

- Over / under treatment
- Ectasia
- Regression
- Decentered ablation

Immediate Post-op July 2014: Topo



Decentered Ablation: Signs / Sx

• Sx:

- Glares / halos
- Ghost images
- Blurred vision

Signs:

- Ablation zone decentration on corneal topography
- Increased higher-order aberrations
- Reduced BCVA improved only with RGP lenses
- Cylinder on ARx and WF differing from MRx
- Reduced VA immediately post-op that fails to improve

Decentered Ablation: Etiologies

Patient factors:

- Poor patient instruction
- Anxiety
- Over-sedation
- Difficulty seeing target
 - High refractive error
 - Exposed stromal bed

Technique:

- Manually tracking the iris
- Improper stabilization of eye
- Pupil centroid shift / cyclotorsion

Decentered Ablation: Management

- Historical:
 - Gas permeable lenses
- Present:
 - PRK: Mild decentration
 - Small (3 4 mm) ablation at original optical zone edge
 - Series of small ablations at decentered ablation edge followed by PTK
 - LASIK:
 - Conventional enhancement
 - Custom-CAP
 - Topo-guided
 - Wavefront-driven

Novel Treatments

- Future:
 - Phorcides / Contura TCN-guided


Topography-Cylinder-Nomogramguided ablation (Phorcides)

- Analytic / Mathematical approach
- Combines topography with true corneal cylinder
- Able to predict significant contributions from posterior cornea and lens


Course Cont.

 Transferred to Civilian provider for LASIK Enhancement using TCN-guided / Contura on 04 Oct 2018.

26 June 2018: Pre-op OD



26 June 2018: Pre-op OS



LASIK Enhancement: 04 Oct 2018


	os
Manifest Rx	+4.20 + 1.25 x 177
Optical / Ablation Zones	6.0mm / 8.7mm
Total ablation depth	110um

SLE: 22 Oct 2018 (Post-op 2.5 wks)

	OD	os
Ext	No ptosis/proptosis	No ptosis/proptosis
LLL	Normal	Normal
C/S	W&Q	W&Q
K	Clear	No epi ingrowth / DLK / microstriae
A/C	D&Q	D&Q
I	R&F	R&F
L	Clear	Clear
Vit	Clear	Clear

S/p LASIK Enhancement

Post-op	OD UCVA	OS UCVA	OS BCVA
POD #1	20/15	20/40-3	
POW #2	20/15	20/50+	20/50
POM #2	20/15	20/40-	20/40



Conclusion: Decentered ablations

- Numerous etiologies
 - i.e. Manually tracking the iris during treatment
- LASIK enhancements remain difficult
 - Varying outcomes
- Treatment continues to improve
 - TCN-guided ablations: outperformed standard LASIK models
 - Enhancements/complicated patients
 - All comers
 - Phorcides: consistent and reliable outcomes on both enhancements and initial LASIK treatments

Special Thanks

- Dr. Gary Legault
- Dr. Mark Lobanoff

References

- Stonecipher K; Parrish J; Stonecipher M. Comparing wavefrontoptimized, wavefront-guided and topography-guided laser vision correction: clinical outcomes using an objective decision tree. Curr Opin Ophthalmol 2018; 29:277-285.
- Manche E; Roe J. Recent advances in wavefront-guided LASIK. Curr Opin Ophthalmol 2018; 29:2786-291.
- Lin D, Manche E. Custom-contoured ablation pattern method for the treatment of decentered laser ablations. JCRS 2004; 30:8:1675-1684.
- Kymionis G, Panagopoulou S, Aslanides I, Plainis S, Astyrakakis N, Pallikaris I. Topographically supported customized ablation for the management of decentered laser in situ keratomileusis. Amer J Ophth 2004; 137:5:806-811.
- Jain AK, Malhotra C, Pasari A, Kumar P, Moshirfar M. Outcomes of topography-guided versus wavefront-optimized laser in situ keratomileusis for myopia in virgin eyes. JCRS 2016; 42:9:1302-1311.
- Stulting RD, Fant BS, Bond W, Chotiner B, Durrie D, Gordon M, Milauskas A, Moore C, Slade S, Randleman JB, Stonecipher K. Results of topography-guided laser in situ keratomileusis custom ablation treatment with a refractive excimer laser. JCRS 2016; 42:1:11-18.

Discussion

- Experience with decentered ablations
 - Treatments utilized
 - Threshold for enhancement
- Military relevance
 - Safety of TCN-guided ablations operationally


Decentered Ablation

Adam H.H. Altman, MD Capt, USAF, MC, FS Ophthalmology, R1 09 Jan 2019


Thank you

Additional slides for reference


26 June 2018: Topo OS




Pre-op 26 June 2018: OS



Post-op: 29 Nov 18





6.8


7.2

7.6 8.0

mm

Curvature


Abs





Advance Eye Clinic

Overview




Sim Ks (3 mm) 39.00 D (8.65 mm) @ 71 38.86 D (8.68 mm) @ 161

Total astigmatism 0.13 D


Central (0-3 mm) 37.39 D (9.03 mm) @ 46 41.15 D (8.20 mm) @ 226 39.31 D (8.59 mm) @ 136 40.34 D (8.37 mm) @ 316

Midperiphery (3-6 mm) 36.38 D (9.28 mm) @ 46 41.02 D (8.23 mm) @ 226 37.80 D (8.93 mm) @ 136 39.42 D (8.56 mm) @ 316

Periphery (6-9 mm) 38.68 D (8.73 mm) @ 46 40.60 D (8.31 mm) @ 226 37.38 D (9.03 mm) @ 136 40.74 D (8.28 mm) @ 316



Rings Image



11/29/2018 10:45:36 AM

Pup. diam	7.8 mm
HVID	12.3 mm
Pup. center	0.1, 0.0
Pho. pup.	5.26 mm
Sco. pup.	7.77 mm



PathFinder II

OS 11/29/2018 10:45:36 AM 100%

Normal

KCN Pattern

Myopic LVC

Hyperopic LVC

Other

Threshold: 25%

63%

(c) 2014 CARL ZEISS MEDITEC **ATLAS**

Revision 3.0.2.0